Literature DB >> 29020600

Trial of Tocilizumab in Giant-Cell Arteritis.

John H Stone1, Micki Klearman2, Neil Collinson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29020600     DOI： 10.1056/NEJMc1711031

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  [How long should treatment with tocilizumab be carried out for giant cell arteritis and how should it be ended (discontinue/taper off)?]

Authors:  J Henes
Journal:  Z Rheumatol       Date:  2020-12-22       Impact factor: 1.372

Review 2.  Looking ahead: giant-cell arteritis in 10 years time.

Authors:  Milena Bond; Alessandro Tomelleri; Frank Buttgereit; Eric L Matteson; Christian Dejaco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

3.  Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.

Authors:  Lili Pan; Juan Du; Jiayi Liu; Hua Liao; Xiaoli Liu; Xi Guo; Jing Liang; Hongya Han; Lixia Yang; Yujie Zhou
Journal:  Clin Rheumatol       Date:  2020-03-06       Impact factor: 2.980

4.  Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.

Authors:  Hubert de Boysson; Maelle Le Besnerais; Félix Blaison; Aurélie Daumas; Pierre-André Jarrot; François Perrin; Nathalie Tieulié; Alexandre Maria; Pierre Duffau; Bruno Gombert; Maxime Samson; Olivier Espitia; Marc Lambert; Arsène Mékinian; Achille Aouba
Journal:  Arthritis Res Ther       Date:  2021-05-19       Impact factor: 5.156

Review 5.  Leveraging Genetic Findings for Precision Medicine in Vasculitis.

Authors:  Marialbert Acosta-Herrera; Miguel A González-Gay; Javier Martín; Ana Márquez
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 6.  Patient Reported Outcomes in Large Vessel Vasculitides.

Authors:  Joanna Robson; Sarah Mackie; Catherine Hill
Journal:  Curr Rheumatol Rep       Date:  2021-01-28       Impact factor: 4.592

7.  TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia.

Authors:  Stefan Weiler; Manfred Nairz
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

8.  Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs.

Authors:  Romilda Sherzay; Torsten Witte; Thorsten Derlin; Marius Hoepfner; Frank M Bengel
Journal:  Diagnostics (Basel)       Date:  2021-06-22

9.  Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis - case report.

Authors:  Michaela Butryn; Sabine Mewes; Eugen Feist; Oliver Beuing; Christian Müller; Jens Neumann
Journal:  BMC Neurol       Date:  2021-06-22       Impact factor: 2.474

10.  COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.

Authors:  Garth W Strohbehn; Brian L Heiss; Sherin J Rouhani; Jonathan A Trujillo; Jovian Yu; Alec J Kacew; Emily F Higgs; Jeffrey C Bloodworth; Alexandra Cabanov; Rachel C Wright; Adriana K Koziol; Alexandra Weiss; Keith Danahey; Theodore G Karrison; Cuoghi C Edens; Iazsmin Bauer Ventura; Natasha N Pettit; Bhakti K Patel; Jennifer Pisano; Mary E Strek; Thomas F Gajewski; Mark J Ratain; Pankti D Reid
Journal:  Clin Pharmacol Ther       Date:  2020-12-10       Impact factor: 6.903
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.